A Phase II Study of M2951 in SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Sponsor: EMD Serono Research & Development Institute, Inc.
Terminated
Study is completed; primary analysis completed.
Other terminated trials from EMD Serono Research & Development Institute, Inc.
- Advanced Solid Tumor · Phase PHASE1 · Dec 2025
- Dermatomyositis · Phase PHASE2 · Jun 2025
- Squamous Cell Carcinoma of the Head and Neck · Phase PHASE3 · Sep 2024
- Head and Neck Cancer · Phase PHASE3 · Aug 2024
- Head and Neck Cancer · Phase PHASE1 · Aug 2024
More terminations from EMD Serono Research & Development Institute, Inc.
Other Systemic Lupus Erythematosus trials with similar outcome
Listed as NCT02975336, this PHASE2 trial focuses on Systemic Lupus Erythematosus and remains terminated or withdrawn. Sponsored by EMD Serono Research & Development Institute, Inc., it has been updated 27 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
27 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 22 earlier versions
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EMD Serono Research & Development Institute, Inc.
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .